STAMFORD, Conn., May 03, 2023 (GLOBE NEWSWIRE) — GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced a clarification regarding the CUSIP number for the Company’s public warrants. As previously disclosed on April 28, 2023, the Company will effect a 1-for-33 reverse…Read More
Latest News GeneDx Announces Clarification Regarding CUSIP Number for Businessfortnight
